Vol. 45 (3): 428-434, May – June, 2019
doi: 10.1590/S1677-5538.IBJU.2019.03.03
DIFFERENCE OF OPINION
Saum Ghodoussipour 1, Giovanni Enrico Cacciamani 1, Andre Luis de Castro Abreu 1
1 USC Institute of Urology and Catherine & Joseph Aresty Department of Urology, University of Southern California, Los Angeles, CA, USA.
Keywords: Prostatic Neoplasms; Prostatectomy; Radiotherapy
BACKGROUND
Prostate cancer (PC) is the most common solid malignancy in men. In 2019, there are expected to be 174,000 new diagnoses in the United States with 31,000 patients ultimately succumbing to their disease (1). Those with more aggressive disease are at a greater risk of local treatment failure and death (2), thus emphasis on the appropriate management for the subset of patients with high risk PC (HRPC) is paramount.
